Relmada Therapeutics (RLMD) Common Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Common Equity data on file, last reported at $218.7 million in Q1 2026.

• Quarterly Common Equity rose 874.72% year-over-year to $218.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.7 million (up 874.72% YoY) and the FY2025 annual result came in at $86.5 million, up 143.55% from the prior year.
• Common Equity grew to $218.7 million in Q1 2026 per RLMD's latest filing, from $86.5 million in the prior quarter.
• Across five years, Common Equity topped out at $218.7 million in Q1 2026 and bottomed at $9.5 million in Q3 2025.
• The 5-year median for Common Equity is $86.5 million (2025), against an average of $100.4 million.
• The widest annual swing landed in 2025, when Common Equity sank 80.12%; it then jumped 874.72% in 2026.
• Tracing RLMD's Common Equity over 5 years: stood at $140.4 million in 2022, then sank by 39.22% to $85.4 million in 2023, then sank by 58.38% to $35.5 million in 2024, then surged by 143.55% to $86.5 million in 2025, then jumped by 152.83% to $218.7 million in 2026.
• Per Business Quant, the three latest RLMD Common Equity figures stand at $218.7 million (Q1 2026), $86.5 million (Q4 2025), and $9.5 million (Q3 2025).

Peer Comparison